The trials CREDENCE, DECLARE TIMI 58, SCORED, and VERTIS-CV all found a statistically significant increase in risk for DKA [6,11,12,16], whereas, EMPA-REG OUTCOME, CANVAS, DAPA-HF, and DAPA-CKD found no difference in risk for DKA with SGLT2-Is or placebo [5,13,14,17]. Here, SLC5A2 is linked to chronic kidney disease.